Drugs / Amisodin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07221240 | Oct 2025 → May 2026 overdue | amyotrophic lateral sclerosis | PRG Science & Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amisodin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07221240 ↗ |
| Route | Oral | “receive a single oral dose of Amisodin or placebo under fasting conditions” NCT07221240 ↗ |